|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
65,690,000 |
Market
Cap: |
18.72(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.285 - $0.285 |
|
Level
I Sector: |
Conglomerates |
Level
II Sector: |
Conglomerates |
Level
III Sector: |
Conglomerates |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Lipocine is clinical-stage biopharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. Co. has a license agreement for the development and commercialization its product candidate, TLANDO®, an oral testosterone replacement therapy comprised of testosterone undecanoate. Co.'s additional pipeline candidates, LPCN 1148 comprising a prodrug of testosterone, testosterone laurate, for the management of decompensated cirrhosis. Co. is conducting a Phase 2 POC study in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148 for the management of sarcopenia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
409,445 |
Total Buy Value |
$0 |
$0 |
$0 |
$190,118 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Higuchi John W. |
Director |
|
2017-05-12 |
4 |
A |
$3.76 |
$64,672 |
D/D |
17,200 |
475,248 |
|
- |
|
Patel Mahesh V. |
President and CEO |
|
2015-09-30 |
4 |
B |
$11.68 |
$47,355 |
D/D |
4,000 |
887,632 |
2.81 |
- |
|
Higuchi John W. |
Director |
|
2015-09-30 |
4 |
B |
$12.68 |
$63,400 |
D/D |
5,000 |
693,382 |
2.39 |
- |
|
Patel Mahesh V. |
President and CEO |
|
2014-11-25 |
4 |
B |
$5.10 |
$10,200 |
D/D |
2,000 |
885,632 |
2.81 |
- |
|
Patel Mahesh V. |
President and CEO |
|
2014-11-24 |
4 |
B |
$5.45 |
$10,900 |
D/D |
2,000 |
883,632 |
2.81 |
- |
|
Ono Richard Dana |
Director |
|
2014-11-19 |
4 |
B |
$5.14 |
$20,560 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
Patel Mahesh V. |
President and CEO |
|
2014-11-14 |
4 |
B |
$5.06 |
$10,120 |
D/D |
2,000 |
881,632 |
2.81 |
- |
|
Patel Mahesh V. |
President and CEO |
|
2014-11-13 |
4 |
B |
$5.05 |
$10,104 |
D/D |
2,000 |
879,632 |
2.81 |
- |
|
Hill Stephen A |
Director |
|
2014-11-13 |
4 |
B |
$4.95 |
$19,800 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|